Literature DB >> 18845619

The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding.

Omar L Francone1, Meihua Tu2, Lori J Royer2, Jian Zhu2, Kimberly Stevens2, Joseph J Oleynek2, Zhiwu Lin2, Lorraine Shelley2, Thomas Sand2, Yi Luo2, Christopher D Kane2.   

Abstract

Lectin-like oxidized LDL (ox-LDL) receptor-1 (LOX-1) is a type-II transmembrane protein that belongs to the C-type lectin family of molecules. LOX-1 acts as a cell surface endocytosis receptor and mediates the recognition and internalization of ox-LDL by vascular endothelial cells. Internalization of ox-LDL by LOX-1 results in a number of pro-atherogenic cellular responses implicated in the development and progression of atherosclerosis. In an effort to elucidate the functional domains responsible for the binding of ox-LDL to the receptor, a series of site-directed mutants were designed using computer modeling and X-ray crystallography to study the functional role of the hydrophobic tunnel present in the LOX-1 receptor. The isoleucine residue (I(149)) sitting at the gate of the channel was replaced by phenylalanine, tyrosine, or glutamic acid to occlude the channel opening and restrict the docking of ligands to test its functional role in the binding of ox-LDL. The synthesis, intracellular processing, and cellular distribution of all mutants were identical to those of wild type, whereas there was a marked decrease in the ability of the mutants to bind ox-LDL. These studies suggest that the central hydrophobic tunnel that extends through the entire LOX-1 molecule is a key functional domain of the receptor and is critical for the recognition of modified LDL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845619     DOI: 10.1194/jlr.M800474-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Inhibitory effect of reinioside C on monocyte-endothelial cell adhesion induced by oxidized low-density lipoprotein via inhibiting NADPH oxidase/ROS/NF-kappaB pathway.

Authors:  Yong-Ping Bai; Chang-ping Hu; Mei-Fang Chen; Kang-Ping Xu; Gui-Shan Tan; Rui-Zhen Shi; Yuan-Jian Li; Guo-Gang Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11       Impact factor: 3.000

Review 2.  Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.

Authors:  Bernard Y K Binder; Priscilla A Williams; Eduardo A Silva; J Kent Leach
Journal:  Tissue Eng Part B Rev       Date:  2015-07-14       Impact factor: 6.389

3.  Molecular mechanism of statin-mediated LOX-1 inhibition.

Authors:  Silvia Biocca; Federico Iacovelli; Sara Matarazzo; Giulia Vindigni; Francesco Oteri; Alessandro Desideri; Mattia Falconi
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 4.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

Review 5.  LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.

Authors:  Barbara Rizzacasa; Elena Morini; Sabina Pucci; Michela Murdocca; Giuseppe Novelli; Francesca Amati
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

6.  Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein.

Authors:  Shraddha Thakkar; Xianwei Wang; Magomed Khaidakov; Yao Dai; Kuppan Gokulan; Jawahar L Mehta; Kottayil I Varughese
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

7.  LOX-1, the Common Therapeutic Target in Hypercholesterolemia: A New Perspective of Antiatherosclerotic Action of Aegeline.

Authors:  Abhilasha Singh; Ashok Kumar Srinivasan; Lakshmi Narasimhan Chakrapani; Periandavan Kalaiselvi
Journal:  Oxid Med Cell Longev       Date:  2019-11-30       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.